What is the recommended management of hypertension, including non‑pharmacologic measures and first‑line medication choices?

Management of Hypertension

For most patients with confirmed hypertension (BP ≥140/90 mmHg), initiate combination therapy with two first-line agents—preferably a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic—targeting BP <130/80 mmHg within 3 months. 1

Non-Pharmacologic Management

Lifestyle modifications are foundational for all patients with elevated BP or hypertension and should be implemented before or alongside pharmacological therapy: 2

• Dietary sodium restriction to <2 g/day with increased potassium intake (unless contraindicated) 1, 2
• Weight loss if overweight or obese, as effects are partially additive with medications 2
• DASH dietary pattern emphasizing fruits, vegetables, whole grains, and low-fat dairy 2
• Regular physical activity with at least 150 minutes of moderate-intensity aerobic exercise weekly 2
• Alcohol moderation or elimination, limiting to ≤2 drinks/day for men and ≤1 drink/day for women 2

These interventions enhance the efficacy of pharmacological therapy and their BP-lowering effects are partially additive. 2

First-Line Pharmacological Agents

The following four drug classes have demonstrated the most effective reduction in BP and cardiovascular events: 1

• ACE inhibitors (e.g., enalapril, lisinopril)
• Angiotensin receptor blockers (ARBs) (e.g., candesartan, losartan)
• Dihydropyridine calcium channel blockers (CCBs) (e.g., amlodipine)
• Thiazide and thiazide-like diuretics (e.g., chlorthalidone, indapamide, hydrochlorothiazide)

Important caveat: Beta-blockers are NOT first-line monotherapy for uncomplicated hypertension but should be combined with other major BP-lowering drug classes when compelling indications exist (angina, post-MI, heart failure with reduced ejection fraction, or heart rate control). 1

Treatment Initiation Strategy

When to Start Combination Therapy

Initiate two-drug combination therapy for: 1

• Confirmed hypertension with BP ≥140/90 mmHg in most patients
• Preferred combinations: RAS blocker + dihydropyridine CCB OR RAS blocker + thiazide/thiazide-like diuretic

Exceptions Requiring Monotherapy or Slower Titration

Consider starting with single-agent therapy or slower up-titration in: 1

• Patients aged ≥85 years
• Moderate-to-severe frailty
• Symptomatic orthostatic hypotension
• Elevated BP (systolic 120-139 mmHg or diastolic 70-89 mmHg) with concomitant indication for treatment
• Limited life expectancy

Fixed-Dose Single-Pill Combinations

Use fixed-dose single-pill combinations whenever possible for patients receiving combination therapy, as this improves adherence and BP control. 1

Treatment Targets

Target BP <130/80 mmHg for most adults <65 years; target systolic BP <130 mmHg for adults ≥65 years. 2 The 2024 ESC guidelines recommend achieving this target within 3 months to retain patient confidence, ensure long-term adherence, and reduce cardiovascular risk. 1

For specific populations: 1

• CKD with eGFR >30 mL/min/1.73 m²: Target systolic BP 120-129 mmHg if tolerated
• History of stroke/TIA: Target systolic BP 120-130 mmHg if BP ≥130/80 mmHg confirmed
• Individualize targets for those with eGFR <30 mL/min/1.73 m² or renal transplantation

Treatment Escalation Algorithm

Step 1: Two-Drug Combination

RAS blocker + CCB or RAS blocker + thiazide/thiazide-like diuretic 1

Step 2: Three-Drug Combination (if BP not controlled)

RAS blocker + dihydropyridine CCB + thiazide/thiazide-like diuretic, preferably as single-pill combination 1

Step 3: Add Spironolactone (if BP not controlled)

Add low-dose spironolactone (25-50 mg daily) to the three-drug regimen 1

Step 4: Resistant Hypertension Management (if spironolactone ineffective/not tolerated)

Consider: 1

• Eplerenone instead of spironolactone
• Beta-blocker (if not already indicated)
• Centrally acting agent (e.g., clonidine)
• Alpha-blocker (e.g., doxazosin)
• Hydralazine
• Potassium-sparing diuretic (e.g., amiloride)

Reinforce lifestyle measures, especially sodium restriction, at every step. 1

Special Population Considerations

Black Patients

Initial therapy should include a diuretic or CCB, either in combination or with a RAS blocker. 1 Chlorthalidone was superior to ACE inhibitors in preventing heart failure and stroke in this population. 1

Heart Failure

• HFrEF/HFmrEF: ACE inhibitor (or ARB if intolerant) or ARNI + beta-blocker + MRA + SGLT2 inhibitor 1
• HFpEF: SGLT2 inhibitors recommended; ARBs and/or MRAs may be considered if BP above target 1

Chronic Kidney Disease

RAS blockers are more effective at reducing albuminuria and are recommended as part of the treatment strategy in hypertensive patients with microalbuminuria or proteinuria. 1

Critical Pitfalls to Avoid

Never combine two RAS blockers (ACE inhibitor + ARB) as this is not recommended and increases adverse events without additional benefit. 1

Timing of medication: Take medications at the most convenient time of day to improve adherence—current evidence does not show benefit of specific diurnal timing on cardiovascular outcomes. 1 Encourage patients to take medications at the same time each day in a consistent setting. 1

Avoid alpha-blockers as first-line therapy as they are less effective for CVD prevention than thiazide diuretics, CCBs, ACE inhibitors, or ARBs. 1

Evidence Supporting Intensive BP Control

A 10 mmHg reduction in systolic BP decreases cardiovascular events by approximately 20-30%. 2 Meta-analyses demonstrate a linear association between achieved systolic BP and cardiovascular mortality risk, with lowest risk at 120-124 mmHg. 1 The SPRINT and ACCORD trials testing systolic BP goals <120 mmHg showed significant reduction in cardiovascular events, supporting more intensive targets in high-risk patients. 1